Vancouver, British Columbia, Canada - TheNewswire - March 16, 2021 - Global Cannabis Applications Corp. ("GCAC" or the "Company") (CNSX:APP.CN) (FSE:2FA) (OTC:FUAPF), a leading medical cannabis chain-of-custody compliance and data platform, is pleased to announce that it has been invited to speak at the Emerging Growth Conference on March 17, 2021. This live, interactive online event will allow shareholders and the extensive investment community to interact with GCAC's CEO, Bradley Moore, in real-time.
Please register here to attend:
An archived webcast will also be made available on EmergingGrowth.com.
The Emerging Growth Conference is in its 3rd year and has grown from 1500 attendees to a projected 4000 for this year. In addition to GCAC, other notable companies presenting are NASDAQ listed, VERB Technology Company and Tonix Pharmaceuticals Holding Corp.
Says GCAC's CEO, Bradley Moore, "GCAC has experienced unprecedented growth in the last 7 months. Recent news reports by Bloombergi show the importance of medical cannabis data capture, data transparency and data security. This is what Efixii was built for and we are delighted to tell this story to all who will listen.”
GCAC has recently announced a series of revenue and partnership deals that empower the $13.4B* global medical cannabis industry's growth with its first-of-a-kind Ethereum 2.0 Blockchain-based EfixiiTM compliance & consumer efficacy software for cultivators to consumers.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services, and other major announcements to the investment community from the convenience of their office in a time-efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
About Global Cannabis Applications Corp.
Global Cannabis Applications Corp. is a global leader in designing, developing, SaaS licensing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green and Efixii platforms are the world's first end-to-end - from patient to regulator - medical cannabis data solutions. They use six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, Ethereum blockchain and GCAC smart rewards. These technologies transparently disclose cannabis chain-of-custody events, thereby enabling patients to provide crowd-sourced medical cannabis efficacy data. Driven by digital and cannabis industry experts, GCAC is focused on generating revenue from SaaS licensing its technology and acquiring high quality cannabis datasets that improve patient outcomes and to become the world’s largest cannabis efficacy data provider.
Phone: +1 (800) 409-5679
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.
Copyright (c) 2021 TheNewswire - All rights reserved.